Trial intelligence / Profile preview

IDP-108 in onychomycosis

NCT01007708Phase 3Completed

Sponsor
Dow Pharmaceutical Sciences
Start
Nov 2009
Primary completion
Dec 2011
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of efinaconazole in onychomycosis, sponsored by Dow Pharmaceutical Sciences. Started Nov 2009; status: completed.

02

Drugs

efinaconazole
03

Conditions

onychomycosis

Beyond the preview

Go deeper on NCT01007708.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01007708.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call